High treatment compliance and tolerability with fitusiran antithrombin-based dose regimen in people with hemophilia A or B, with or without inhibitors: ATLAS-OLE study
Mindy Simpson(Indiana Hemophilia and Thrombosis Center), Erin Cockrell(St. Joseph's Hospital), Steven W. Pipe(University of Michigan), Sandra Casiano(AVEO Oncology (United States)), Lila-Sabrina Fetita(Sanofi (France)), Chuanwu Zhang(AVEO Oncology (United States)), Abhimanyu Yarramaneni(C3I (United States)), Jing Sun(Qiqihar University), Kaan Kavaklı, Chia-Yau Chang(Taipei Medical University Hospital), Arta Subagiarta(AVEO Oncology (United States)), Chur-Woo You(Eulji University)
Cited by 0
Related Papers
Genome sequence and genetic diversity of the common carp, Cyprinus carpio
|Nature Genetics|2014|677
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|494
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex
|Nature Genetics|2003|314